Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:RVPH 24 October 2025 - 24 December 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals shares fell to $0.32 on December 24, 2025, after the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine before a New Drug Application. The company said the new trial, RECOVER-2, could cost $60 million and delay potential approval to late 2028. Reviva plans to start the trial in the first half of 2026, pending financing.
24 December 2025
···
Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) traded around $0.69 per share mid-session December 10, up 10% on the day but still down 72% over the past year. Market cap stood near $78–80 million. On December 9, call options volume spiked 458% above average as traders speculated on upcoming catalysts. The company’s lead drug, brilaroxazine, recently completed Phase 3 trials in schizophrenia.
10 December 2025
··
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

RVPH shares closed at $0.57 on Oct 24 after a volatile month, swinging between $0.26 and $0.84. The stock surged 28% on Oct 23 following recent Phase 3 trial results for brilaroxazine and news of an upcoming FDA meeting. Reviva raised about $19 million this year to fund its CNS pipeline. Analyst targets average $6.25, implying a potential 1,000% upside.
24 October 2025
···
Go toTop